

**Hydroxychloroquine alone or in combination with azithromycin  
to prevent major clinical events in hospitalised patients with  
coronavirus infection (COVID-19): rationale and design of a  
randomised, controlled clinical trial**

**Submitted on May 19<sup>th</sup> 2020**

**Electronic Supplementary Material**

**Appendix 1**

*Steering Committee for Coalition*

COALITION COVID-19 Brasil I Investigators

Alexandre B Cavalcanti, Fernando G Zampieri, Luciano CP Azevedo, Regis Rosa, Álvaro Avezum, Viviane C Veiga, Renato D. Lopes, Letícia Kawano-Dourado, Lucas P Damiani, Adriano J Pereira, Ary Serpa-Neto, Remo Furtado, Bruno Tomazini, Fernando A Bozza, Israel Maia, Maicon Falavigna, Thiago C Lisboa, Henrique Fonseca, Flávia R Machado, Otavio Berwanger

## Appendix 2

### SPIRIT 2013 Checklist

Section/item	Item	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	2
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	9,11
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3
	6b	Explanation for choice of comparators	3
Objectives	7	Specific objectives or hypotheses	4
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	4
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5,6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6

	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	9
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	4,5
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	4,10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	10
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	6,8,11
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	6

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9,10
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	9
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	10,11
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11,12
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	11,12
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	10
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	7,8
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	12
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA

Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	13
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	13
	31b	Authorship eligibility guidelines and any intended use of professional writers	13
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	13
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA, per Brazilian law
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA

## Appendix 3

### *Statistical Analysis Plan (v3.0) for Study Protocol v4.0*

#### *Sample Size and Power*

We will include 630 cases. We are accepting suspected cases in the study because PCR results for SARS-CoV-2 currently may take up to 5 days to be available on many Brazilian websites. Among the 630 patients, we expect to include 510 confirmed cases (with positive CRP for SARS-Cov-2), which will be the cases considered in the analyses.

Considering an ordinal outcome with six stages with the probabilities 35%, 15%, 20%, 10%, 10%, 10%, with the expected values derived from the study of Cao et al. [1], respectively for stages 1 to 6, under the model of proportional odds ratios for the accumulated probabilities for the outcome levels, a sample of 210 cases per arm (630 cases) has 80% power to detect a reason odds of an average of 1.76 between the arms (two by two), with a 5% significance level, with Bonferroni adjustment for multiple comparisons ( $\alpha = 5\% / 3$  for each two by two comparison).

Considering the first 120 patients included in the study, we found that the distribution of the ordinal outcome in 7 levels was: 1) Outpatient, without limitation in daily activities, 60%; 2) Outpatient, with limitations in daily activities, 19%; 3) Patient in the hospital, without supplemental oxygen, 7%; 4) Patient in the hospital, with supplemental oxygen, 1%; 5) Patient in the hospital on non-invasive ventilation or high flow cannula, 1%; 6) Patient on mechanical ventilation, 5%; 7) Death: 7%. Assuming that this distribution represents the true distribution in the study population, with 510 patients confirmed in the main analysis, we will have 80% power to detect an odds ratio of 2.0 between the arms (two by two comparisons), with a significance level of 5%, with Bonferroni adjustment for multiple comparisons ( $\alpha = 5\% / 3$  for each comparison two by two).

#### *Interim Analysis*

The three interim analyses are planned when we reached 120 randomised patients with the completed 15-day outcome, a second analysis with 315 patients and a third with 504. The recruitment rate for this study is fast and it is possible that by the time the number of patients in the second or third interim analysis has completed 15 days of follow-up the entire sample has already been included. If this happens, there would be no reason to perform second or third interim analyses and these will be cancelled.

We expect that at this time we will be close to the total sample, so that we will use the strict Haybittle-Peto limit [2], considering  $p < 0.001$ , to stop the safety study, and an even more restrictive p-value for benefit benefit interruption ( $p < 0.0001$ ), so we will not adjust the final values of the hypothesis test for sequential analysis. The external data monitoring committee will use, along with the above limits, external evidence (if available) as well as the security profile of the study's own data to issue its recommendation.

By using p values  $< 0.001$  and  $p < 0.0001$  in the interim analysis for safety and efficacy, Haybittle's article [2] suggests that the p-value in the final analysis should not be correct. We would have a significance level for the final analysis at approximately 4.7%, to maintain 5% of the overall significance level, so it suggests that you do not adjust p-value when using these criteria. The p-value for multiple comparisons will not be corrected by the Bonferroni method in each interim analysis, but only in the evaluation of the final primary

outcome of the study. The blocking of the database will be performed after obtaining 15 days of follow-up of all patients and all the necessary actions to obtain follow-up are performed. All interim analyses will be made available to national regulatory agencies.

### Basic reporting principles:

The baseline characteristics of the patients will be displayed as the supplementary table 1 (sTable 1) below:

sTable 1 – Baseline features of included patients

	<b>Hydroxychloroquine + Azithromycin (HCQA)</b>	<b>Hydroxychloroquine (HCQ)</b>	<b>Control (Cont)</b>
	n=xxx	n=xxx	n=xxx
<b>Age, mean (DO)</b>	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
<b>Female gender, n (%)</b>	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>COVID-19</b>			
Positive	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Negative	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Unavailable	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Comorbidity</b>			
Hypertension	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Diabetes	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Previous smoker	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Current smoker	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Obesity	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Solid cancer	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Haematological Cancer	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Heart Failure	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
COPD	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
AIDS	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Chronic kidney disease	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
On dialysis	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Cirrhosis	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Asthma	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Neuromuscular disease	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Previous myocardial infarction	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Previous Medication</b>			
Corticosteroids	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
ACE inhibitor	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
ARBs	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Aspirin	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Patient Location at Enrollment</b>			
Emergency Room	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Ward	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Intensive Care Unit	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Clinical Data</b>			
Systolic blood pressure, mmHg, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Diastolic blood pressure,	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x

mmHg, mean (SD)			
Heart rate, bpm, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Respiratory rate, rpm, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Peripheral O <sub>2</sub> saturation, %, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
<b>Oxygen Support</b>			
None	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Nasal Catheter			
Venturi Masck	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Vasopressor</b>			
No	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Norepinephrine ≤ 0.1 mcg/kg/min	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Norepinephrine > 0.1 mcg/kg/min	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Laboratorial Data</b>			
Creatinine, mg/dL, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
D-dimer, ng/dL, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Hemoglobin, g/dL, mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Leukocytes totais, 1/mL, mediana [IQR]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]
Platelets, 1/mm <sup>3</sup> , mean (SD)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Lymphocytes, 1/mL, mediana [IQR]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]
Lactate (mg/dL)	xx.x ± xx.x	xx.x ± xx.x	xx.x ± xx.x
Troponin, mediana [IQR]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]
<b>Other drugs prescbed</b>			
Ceftriaxone	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Ceftaroline	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Piperaciline/Tazobactan	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Oxaciline	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Vancomycin	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Carbapenems	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Quinolones	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Oseltamivir	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Lopinavir+Ritonavir	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Corticosteroids			
Hydrocortisone ≤ 200 mg/day	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Hydrocortisone > 200 mg/day	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
<b>Days from illness onset to randomisation – median (IQR)</b>	xx.x [xx.x - xx.x]	xx.x [xx.x - xx.x]	xx.x [xx.x - xx.x]
<b>Time between admission and enrollment, median [IQR]</b>	xx.x [xx.x - xx.x]	xx.x [xx.x - xx.x]	xx.x [xx.x - xx.x]



The main analysis study population will comprise all patients who have been randomised and have confirmed COVID-19 (modified intention-to-treat population), using the group allocated as variable, regardless of the medication administered.

The main objective is to assess the effect of the treatment with hydroxychloroquine compared to not treating with hydroxychloroquine, and the effect of combined treatment with hydroxychloroquine and azithromycin compared to treating with hydroxychloroquine only, in adult patients with confirmed COVID-19 in an ordinal scale in at day 15 after randomisation: 1) Out-patient, without limitation in activities; 2) Out-patient, with limited activity; 3) Patient in the hospital, without supplemental oxygen; 4) Patient in the hospital, with supplemental oxygen; 5) Patient in the hospital on non-invasive ventilation or high flow cannula; 6) Patient on mechanical ventilation; 7) Death. The ordinal scale will be presented as median [quartiles], and as a percentage in each stage as described in sTable 2. The treatment effect will be presented as proportional odds ratio, with 95% confidence interval and P-value for all combinations two by two: HCQA versus HCQ, HCQA versus Control and HCQ versus Control. We will use a mixed logistic regression model assuming proportional odds ratios with random intercept by site adjusted for for age and need of oxygenation at admission (stratification variable). For these hypothesis tests we will consider adjustment for multiple Bonferroni comparisons, using 5%/3 as significance level for each comparison.

The effect on the ordinal outcome at day 7 will be estimated with mixed ordinal logistic regression model assuming proportional odds ratios adjusted for age and need for oxygenation in randomisation, with random intercepts according to the centre.

It is conceivable that odds proportionality will not hold in the primary outcome or at day 7. In this scenario, we plan to group the 7-level ordinal scale into a 3-level ordinary scale (patient not at hospital, patient at the hospital, or dead). If proportionality still does not hold, we will not attempt to calculate proportional odds ratios models and all cumulated ordinal dichotomization will only be presented as independently logistic binary regressions as presented in sTable 2.

For days free from respiratory support within 15 (DAFOR15) days will use generalized additive models [3] assuming beta-binomial distribution to estimate the treatment mean differences.

Renal dysfunction within 15 days, need of noninvasive ventilation or high-flow nasal cannula within 15 days, need of mechanical ventilation within 15 days, thromboembolic complications within 15 days, will be tested with mixed logistic regression. For the outcome of renal dysfunction, if there is no creatinine collection at admission, we will estimate the patient's basal creatinine with the modified formula MDRD:  $\text{MDRD creatinine} = 0.74 - 0.2 \text{ (if female)} + 0.003 \times \text{age (in years)}$  [4]. We will not consider the race component due to specific characteristics of the Brazilian population.

The length of hospitalization will be presented as mean and standard deviation and compared between studies with estimated mean difference in mixed generalized linear models with Gamma, Normal or Poisson distribution, which best fit the data.

Hospital mortality will be tested primarily via mixed logistic regression, assuming we will have complete information from all patients at the end of the study. Otherwise, if patients have been transferred to other institutions and there is missing information due to the actual crisis, hospital mortality will be tested with cox proportional risk models with random local interception (frailty model) and a risk rate will be presented as a measure of effect. All outcomes will be adjusted for age and need for oxygenation at randomisation.

The analyses will be carried out with R software (R Core Team, 2019) [5].

Preprint, not peer reviewed

sTable 2 – Main Results Presentation

Outcomes	HCQA	HCQ	Cont	Effect Size					
				HCQA vs. HCQ		HCQA vs. Cont		HCQ vs. Cont	
	n=xxx	n=xxx	n=xxx	Effect measure [CI 95%]	p	Effect measure [CI 95%]	p	Effect measure [CI 95%]	p
<b>Ordinal outcome at 15 days, median [IQR]</b>	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Category 1-6 vs. 7 (alive vs dead)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1-5 vs. 6-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1-4 vs. 5-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1-3 vs. 4-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1-2 vs. 3-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1 vs. 2-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
<b>Secondary outcomes</b>									
Ordinal outcome at 7 days, median [IQR]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	x.xx [x.xx - x.xx]	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Category 1/2-6 vs. 7 (alive vs dead)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1/2-5 vs. 6-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1/2-4 vs. 5-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1/2-3 vs. 4-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Category 1/2 vs. 3-7	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx	x.xx [x.xx; x.xx]	x.xx
Need of HFNC or NIV within 15 days, n (%)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Need of mechanical ventilation within 15 days, n (%)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Length of hospital stay, days, mean (SD)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	MD x.xx [x.xx; x.xx]	x.xx	MD x.xx [x.xx; x.xx]	x.xx	MD x.xx [x.xx; x.xx]	x.xx
In-hospital death, n (%)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Thromboembolic complications within 15 days, n (%)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Acute kidney injury within 15 days, n (%)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx	OR x.xx [x.xx; x.xx]	x.xx
Days alive free from respiratory support within 15 days, mean (SD)	x.xx (x.xx)	x.xx (x.xx)	x.xx (x.xx)	MD x.xx [x.x; x.xx]	x.xx	MD x.xx [x.xx; x.xx]	x.xx	MD x.xx [x.xx; x.xx]	x.xx

**Legend:** HFNC (High flow nasal catheter); IQR (Interquartile range); CI (confidence interval); SD (standard deviation); MV (mechanical ventilation) NIV (Non-invasive ventilation); LOS (length-of-stay); OR (Odds Ratio); MD (Mean difference); HR (Hazard Ratio)

### *Sensitivity analyses*

We should also perform analyses to assess treatment effects on the primary and secondary outcomes considering all randomised patients and report as supplementary material. Additionally, we will also perform sensitivity analysis for the primary outcome in the following groups:

1. Definitive, probable, and possible COVID-19 patients
2. Definitive and probable COVID-19 patients

We should also analyse treatment effects on the primary outcome considering all patients who have confirmed COVID and who received at least one dose of the medication to which they were allocated, that is, excluding patients did not take any dose of the allocated medications. For safety analyses we will consider a third population (called the safety population), considering the medication administered, regardless of the allocated group.

### *Subgroup Analyses*

Will also perform subgroup analysis adding an interaction parameter with group in the main model for:

1. Duration of disease ( $\leq 7$  days vs  $> 7$  days).
2. Age ( $< 60$  years and  $\geq 60$  years).
3. Need for oxygen at randomisation.

Finally, the ordinal score (secondary outcome) will be available daily for each patient up to 15 days. For the daily evaluation we will not be able to distinguish between stages 1 and 2 (at home without or with limitations on activities). These results will be presented in an alluvial graph for each arm. The conditional probabilities of change in stages (1/2 to 7) will be estimated via Bayesian Networks to better describe the time when the intervention can change the distribution of the score or estimate the probability of discharge. For example, Bayesian networks allow estimating the probability of discharge on day 6 if the patient is without oxygenation support on day 5. We plan to present this independent manuscript analysis with and report transition probabilities and relative risk (with confidence intervals obtained through bootstrap techniques) for relevant scenarios.

### *Treatment adherence report*

Patients should receive the medications allocated by randomisation up to 7 days after inclusion in the study. However, because it is an open study, it is possible that deviations in the protocol happen. Thus, we will describe the use of study medications in all arms until the 15th day of follow-up. The rate of medication uses by patient-days up to the seventh day of follow-up will be described for the three groups.

### *Safety outcomes*

Safety outcomes, in addition to any other serious adverse event not listed as safety outcomes, duly reported to national regulatory agencies and the data monitoring committee, will be described for each arm and

compared by Chi-square test using safety population. We will present P-values not adjusted for multiplicity of comparisons for safety outcomes.

### *References*

1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 18 March 2020, E-pub
2. Haybittle JL (1971) Repeated assessments of results in clinical trials of cancer treatment. *Br. J. Radiol.* 44 (526): 793–797.
3. Stasinopoulos M, Rigby R. *gamlss.dist: Distributions for Generalized Additive Models for Location Scale and Shape*. 2020 R package version 5.1-6. <https://CRAN.R-project.org/package=gamlss.dist>
4. Závada J, Hoste E, Cartin-Ceba R, Calzavacca P, Gajic O, Clermont G, Bellomo R, Kellum JA; AKI investigators. A comparison of three methods to estimate baseline creatinine for RIFLE classification. *Nephrol Dial Transplant*. 2010 Dec;25(12):3911-8.
5. R Core Team (2019). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.

## **Appendix 4**

### **DMC Charter v1.0 for Protocol v 3.0**

#### *Principles of the Data Monitoring Committee (DMC)*

The proper execution of the research project depends on the interface between the scientific committee, participating centres and the data monitoring committee (DMC). This document explains the functions of the study sponsor, the law committee, and the DMC. It will be presented to the DMC at the time of its constitution and may be amended as discussed by the members present. The conduct of the study is the sole responsibility of the steering committee, which undertakes to send correct and updated data to the DMC whenever requested or in the occurrence of adverse events or at the stipulated moments of the interim analyses

#### *Role of the funding source*

The COVID-19 Brazil Coalition is a partnership of academic leaders who designed a study initiated by a double-sponsored researcher, the Coalition in conjunction with EMS Pharmaceutical Company, responsible for delivering the study drug. However, because EMS is not involved in the design or conduct of the test, it will have no role in the DMC's choices, in appointing members, or in the design of this regulation. The decision to interrupt or continue the trial on the recommendation of the DMC will be entirely the responsibility of the Academic Steering Committee (SC), without influence or supervision of the EMS. However, EMS will be notified of any decision of the steering committee as soon as the decision is made.

#### *Of the functions of the steering committee:*

The functions of the steering committee are:

1. Monitor the conduct of the study, as well as the collection and quality of the study data
2. Review scheduled DMC reports, with aggregated hidden data (i.e. all subjects, not separated by treatment group)
3. Provide joint review and approval of minutes of open and final sessions of the DMC data review meetings
4. Accept or reject DMC recommendations. The DMC shall be notified in writing of the response to any recommendations, including the reasoning in which the recommendations are not accepted
5. Communicate the recommendations of the DMC for changes in the conduct of the study to the researchers, who in turn communicate them to the Ethics Committees of each site and to the National Council of Ethics in Research (CONEP) and to the National Health Surveillance Agency (ANVISA). Communication on the DMC with researchers will be limited to formal requests for changes in the conduct of the study and will not include information on the conduct of DMC meetings
6. The implementation of changes to the protocol is in accordance with the DMC recommendations.

#### *Functions of the Data Monitoring Committee*

The DMC is responsible for supervising the accumulation of data related to safety and efficacy. The DMC will assess and provide recommendations on the following aspects:

1. Study protocol
2. DMC Charter (this document)
3. Statistical analysis plan
4. Collected data and security monitoring procedures
5. Security events

DMC members will undertake to meet once at the beginning of the study, at each interim analysis and whenever they deem it necessary or at the request of the steering committee, especially when new evidence emerges about the therapies being studied or when adverse events are reported. After each meeting, the DMC will recommend one of the following written actions to the Steering Committee:

1. Continue the study according to the protocol and any related changes
2. Modify the study protocol. Modifications may include, but are not with others, changes in inclusion/exclusion criteria, frequency of safety monitoring, changes in study procedures
3. Pause inclusion, with pending resolution of a specified problem
4. Interrupt the study

The DMC is a multidisciplinary group, independent of the steering committee, composed of two clinicians and one statistician. It will persist until the study is completed. Additional experts on the subject can be consulted by the DMC as needed. The statistician appointed by the President of the DMC will perform independent statistical analyses and have unlimited access to the entire study database. However, the analysis plan of the independent statistician of the DMC should follow the same principles described in the statistical analysis plan of the study.

To protect the scientific integrity of the study under review, all Members of the DMC agree to keep all information in absolute secrecy and will not disclose data, findings, or decisions outside the scope of communication defined in this Charter. Materials provided to DMC for analysis are highly confidential and should not be disclosed in any way to unauthorized third parties. DMC members who develop significant potential or perceived conflicts of interest during the study may be asked to resign.

The first DMC meeting will be an organizational meeting to formally establish the DMC and fully familiarize it with the protocol and interim review plan. They will also offer the DMC the opportunity to recommend final reviews of the review plans, the DMC Charter and the communication plan between the DMC and the right-wing committee. The timing of the meetings will depend on the deadlines of the three pre-specified intermediate analyses (see below). DMC members formally vote on all recommendations to be submitted to the steering committee. To vote, a Member of the DMC must be present at the meetings convened. A simple majority vote of the members transmits a proposal, motion or recommendation to the academic SC. Due to the need to find proven effective treatment for COVID-19 in the current pandemic scenario, the DMC recommendations duly voted and approved are transmitted in writing or by teleconference from the President of the DMC to the steering committee expeditiously, at the latest within the established deadline. The meetings will consist of open and closed parties. During the initial open part of a meeting, a steering committee member

will conduct a brief presentation related to the status of the trial, its conduct, and any concerns, and will be available for questions from DMC members. The closed session, which will take place immediately, will be attended only by DMC members. All meetings will be held by videoconference.

*From the role of the Chair of the DMC:*

1. Hold all DMC meetings and ensure that all relevant data is reviewed
2. Ensure that only DMC members are present during the analysis and deliberation of the DMC data
3. Approve written minutes of all closed sessions of the DMC meetings
4. Create and archive written minutes of all executive sessions of DMC meetings. These minutes will remain confidential only to DMC members until after the database has been blocked and the sponsor's disclosure.
5. Arrange additional consultations with subject matter experts as needed.

*Initial proposal of the statistical analysis plan and stop rules:*

General principles and interim analyses: We plan to conduct the first interim analysis when we reach 120 randomised patients with completed 15-day outcomes. We anticipate that enrolment rate will be fast, so that the enrolment of the total sample size (630 patients) will occur only a few days after the first interim analysis and before the 15-day follow up of half the sample size has been reached. Therefore, a second interim analysis with half the sample size or more is unlikely to be conducted.

We will use the strict Haybittle-Peto limit, considering  $p < 0.001$ , to interrupt the study for safety, and an even more restrictive  $p$ -value for benefit interruption ( $p < 0.0001$ ), so we will not adjust the final values of the hypothesis test for sequential analysis.

When using  $p$  values  $< 0.001$  and  $p < 0.0001$  in the interim analysis for safety and efficacy, Haybittle (1971) suggests that the  $p$ -value should not be correct in the final analysis. We would have a significance level for the final analysis at approximately 4.7%, to maintain 5% of the overall significance level, so it suggests that you do not adjust  $p$ -value when using these criteria. The book Jennison C and Turnbull (1999) brings more details comparing stop criteria for sequential tests. The  $p$ -value for multiple comparisons will be corrected by the Bonferroni.

The locking of the database will be performed after obtaining 15 days of follow-up of all patients and all the necessary actions to obtain follow-up are performed. The main analysis will be made considering the principle of intention to treat. The main outcome will be evaluated by generalized additive models assuming beta-binomial distribution and random intercept by site, all comparisons two by two will be performed without any  $p$ -values correction. Binary outcomes will be evaluated by logistic regression model. Continuous outcomes will be made by linear regression or mixed models for repeated variables, as appropriate. The models will be adjusted for age and oxygenation on admission. Other analyses are discussed on the SAP (Appendix 3). The analyses will be carried out with the help of R software (R Core Team, 2019).

*Safety stop standards will follow the following design*



If there is a general increase in severe adverse events at 14 days with a two-tailed alpha threshold  $<0.001$ , or an increase in ventricular arrhythmias at 14 days with a two-tailed alpha threshold  $<0.001$ . The DMC will consider efficacy data together with safety information to consider stopping the study. For example, if the incidence of ventricular arrhythmias is increased with combined therapy with a  $P<0.001$  value, but there is some sign of reduction or superiority of mortality to the primary endpoint, the DMC may consider moderating the decision to stop for safety, or may recommend excluding patients at high risk of ventricular arrhythmias (those with previous heart disease, for example) or choose to wait for the next interim analysis for weighting. To do this, the DMC will have access to the entire study database required for this specific intermediate analysis and may request additional data if necessary. If the study is not interrupted after any intermediate analysis, the alpha thresholds for severe adverse events or ventricular arrhythmias will not be adjusted in the final statistical analysis. The occurrence of other non-severe adverse events (such as nausea, vomiting, or elevation of liver enzymes without repercussion) will also be weighted by DMC.

Additionally, the DMC will consider other factors outside the rigid limits mentioned above to prepare a recommendation on the study. Safety and efficacy findings often need to be weighed along with external evidence outside the rigid limits. We believe that the DMC is free to carry out such consideration and provide its opinion in these terms.

#### *Final considerations*

This document contains initial provisions on the functioning and interaction between monitoring and data security committee and steering committee. It will be evaluated by the DMC along with protocol and statistical analysis plan. The DMC may suggest changes to any documents mentioned, which are discussed by the steering committee and submitted to regulatory agencies, if applicable, in the form of amendments.